The test will be based on a patient’s serum but the targe of the test has not been announced. It will either be based on an immune complex transfer methods based on Sysmex’ HISCL analyzers, or a super-resolution molecular imaging of a fluorescence-labeled target protein.

Eisai news release February 16, 2016